Home > Full Text Reviews > Drug Class Review: Thiazolidinediones:...
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cover of Drug Class Review: Thiazolidinediones

Drug Class Review: Thiazolidinediones

Final Report Update 1

Drug Class Reviews

Susan L Norris, MD, MPH, Susan Carson, MPH, Sujata Thakurta, MPA:HA, and Benjamin KS Chan, MS.

Oregon Evidence-based Practice Center, Oregon Health & Science University, Mark Helfand, MD, MPH, Director
Portland (OR): Oregon Health & Science University; 2008 Aug.
Copyright and Permissions

There are 2 thiazolidinediones approved for prescription use in the United States, rosiglitazone maleate (Avandia) and pioglitazone hydrochloride (Actos®). Both drugs are approved by the United States Food and Drug Administration for use in adults for the treatment of type 2 diabetes, either as monotherapy or in combination with insulin, metformin, or sulfonylurea when diet, exercise, and a single agent does not result in adequate glycemic control. Neither drug is currently approved for use in prediabetes or the metabolic syndrome. The objective of this review was to compare thiazolidinediones in the treatment of type 2 diabetes, prediabetes, and the metabolic syndrome.

Contents

The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.

Suggested citation:

Norris SL, Carson S. Drug class review: Thiazolidinediones. 2008. http://www.ohsu.edu/drugeffectiveness/reports/final.cfm

The Agency for Healthcare Research and Quality has not yet seen or approved this report.

The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.

Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

PMID: 20496456

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...